EP3103449A3 - Médicaments pour usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique - Google Patents

Médicaments pour usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique Download PDF

Info

Publication number: EP3103449A3
Authority: EP; European Patent Office
Prior art keywords: hyaluronic acid; topical use; medicines; activating; sulfated hyaluronic
Prior art date: 2009-05-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16178620.7A

Other languages

German (de)

English (en)

Other versions

EP3103449B1 (fr

EP3103449A2 (fr

Inventor

Matteo D'este

Giovanni Gennari

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fidia Farmaceutici SpA

Original Assignee

Fidia Farmaceutici SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-14

Filing date

2010-05-14

Publication date

2017-02-15

2010-05-14 Application filed by Fidia Farmaceutici SpA filed Critical Fidia Farmaceutici SpA

2010-05-14 Priority to SM20190015T priority Critical patent/SMT201900015T1/it

2010-05-14 Priority to EP18185228.6A priority patent/EP3417855B1/fr

2016-12-14 Publication of EP3103449A2 publication Critical patent/EP3103449A2/fr

2017-02-15 Publication of EP3103449A3 publication Critical patent/EP3103449A3/fr

2018-10-17 Application granted granted Critical

2018-10-17 Publication of EP3103449B1 publication Critical patent/EP3103449B1/fr

Status Active legal-status Critical Current

2030-05-14 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Oral & Maxillofacial Surgery (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Birds (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Transplantation (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)

EP16178620.7A 2009-05-14 2010-05-14 Médicaments pour usage topique à base d'acide hyaluronique sulfaté pour le traitement de caillots de fibrine et de thrombi Active EP3103449B1 (fr)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
SM20190015T SMT201900015T1 (it)	2009-05-14	2010-05-14	Medicamento per uso topico a base di acido ialuronico solfatato per il trattamento dei coaguli di fibrina e dei trombi
EP18185228.6A EP3417855B1 (fr)	2009-05-14	2010-05-14	Compositions pharmaceutiques pour usage topique à base d'acide hyaluronique sulfaté comme promoteur de l'absorption cutanee

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITPD2009A000134A IT1397246B1 (it)	2009-05-14	2009-05-14	Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
EP10721126.0A EP2429515B1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique
PCT/EP2010/003050 WO2010130468A1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
EP10721126.0A Division EP2429515B1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique
EP10721126.0A Division-Into EP2429515B1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18185228.6A Division EP3417855B1 (fr)	2009-05-14	2010-05-14	Compositions pharmaceutiques pour usage topique à base d'acide hyaluronique sulfaté comme promoteur de l'absorption cutanee
EP18185228.6A Division-Into EP3417855B1 (fr)	2009-05-14	2010-05-14	Compositions pharmaceutiques pour usage topique à base d'acide hyaluronique sulfaté comme promoteur de l'absorption cutanee

Publications (3)

Publication Number	Publication Date
EP3103449A2 EP3103449A2 (fr)	2016-12-14
EP3103449A3 true EP3103449A3 (fr)	2017-02-15
EP3103449B1 EP3103449B1 (fr)	2018-10-17

Family

ID=41226841

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP10721126.0A Active EP2429515B1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique
EP18185228.6A Active EP3417855B1 (fr)	2009-05-14	2010-05-14	Compositions pharmaceutiques pour usage topique à base d'acide hyaluronique sulfaté comme promoteur de l'absorption cutanee
EP16178620.7A Active EP3103449B1 (fr)	2009-05-14	2010-05-14	Médicaments pour usage topique à base d'acide hyaluronique sulfaté pour le traitement de caillots de fibrine et de thrombi

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
EP10721126.0A Active EP2429515B1 (fr)	2009-05-14	2010-05-14	Nouveaux médicaments à usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique
EP18185228.6A Active EP3417855B1 (fr)	2009-05-14	2010-05-14	Compositions pharmaceutiques pour usage topique à base d'acide hyaluronique sulfaté comme promoteur de l'absorption cutanee

Country Status (15)

Country	Link
US (4)	US9504708B2 (fr)
EP (3)	EP2429515B1 (fr)
CN (1)	CN102427808B (fr)
CA (2)	CA2995610C (fr)
ES (3)	ES2601681T3 (fr)
HR (1)	HRP20161574T1 (fr)
HU (1)	HUE030673T2 (fr)
IT (1)	IT1397246B1 (fr)
LT (1)	LT2429515T (fr)
PL (1)	PL2429515T3 (fr)
PT (1)	PT2429515T (fr)
RU (3)	RU2543354C2 (fr)
SI (1)	SI2429515T1 (fr)
SM (3)	SMT202000522T1 (fr)
WO (1)	WO2010130468A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102177180A (zh)	2008-04-04	2011-09-07	犹他州大学研究基金会	烷基化半合成的糖胺聚糖醚及其制备和使用方法
US8343942B2 (en) *	2008-04-04	2013-01-01	University Of Utah Research Foundation	Methods for treating interstitial cystitis
IT1397247B1 (it) *	2009-05-14	2013-01-04	Fidia Farmaceutici	Nuovi agenti regolatori dell'attivita' citochinica
US20130209531A1 (en)	2010-06-08	2013-08-15	University Of Utah Research Foundation	Applications of partially and fully sulfated hyaluronan
CA2830933A1 (fr)	2011-03-23	2012-09-27	University Of Utah Research Foundation	Procedes pour le traitement ou la prevention d'inflammation urologique
ES2991296T3 (es)	2014-10-17	2024-12-03	Fidia Farm Spa	Sistema terapéutico dérmico de alta adhesividad
ITUB20155623A1 (it) *	2015-11-16	2017-05-16	Fidia Farm Spa	Processo migliorato per la produzione di HA solfatato di elevata purezza
US11576925B2 (en) *	2016-04-25	2023-02-14	Mizhou Hui	Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments
WO2018053111A1 (fr)	2016-09-15	2018-03-22	University Of Utah Research Foundation	Compositions de gélification in situ pour le traitement ou la prévention d'une inflammation et d'une lésion tissulaire
IT201600117042A1 (it) *	2016-11-18	2018-05-18	Fidia Farm Spa	Acidi ialuronici solfatati funzionalizzati con dopamina
CN111228653A (zh)	2018-11-13	2020-06-05	格莱科米拉治疗公司	用电离辐射加强癌症治疗的方法
IT201900003887A1 (it)	2019-03-18	2020-09-18	Fidia Farm Spa	Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
KR102542329B1 (ko) *	2019-12-23	2023-06-13	주식회사 엘지화학	항염 또는 항혈관신생용 약제학적 조성물
US20220160689A1 (en) *	2020-09-29	2022-05-26	Ziropa, Inc.	Compositions and methods for pain relief and numbing
CN113754795B (zh) *	2021-10-19	2023-03-10	澳门大学	磺酸化透明质酸类化合物、其制备方法及其应用
WO2024164213A1 (fr) *	2023-02-09	2024-08-15	谢彦晖	Traitement de la dermatite atopique avec de l'interleukine 2 modifiée par du polyéthylène glycol, un glucocorticoïde et de l'acide hyaluronique

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995025751A1 (fr) *	1994-03-23	1995-09-28	Fidia Advanced Biopolymers Srl	Nouveaux polysaccharides sulfates du type heparine
GB2317182A (en) *	1996-09-11	1998-03-18	Johnson & Johnson Medical	Sulphated polysaccharides and uses thereof in medical treatment
WO1998045335A1 (fr) *	1997-04-04	1998-10-15	Fidia Advanced Biopolymers, S.R.L.	Composes d'acide hyaluronique n-sulfates, leurs derives et leur procede de preparation
DE19813234A1 (de) *	1998-03-26	1999-09-30	Knoell Hans Forschung Ev	Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JP2001163789A (ja) *	1999-12-13	2001-06-19	Maruho Co Ltd	マトリックスメタロプロテアーゼ阻害用医薬組成物
US6719986B1 (en) *	1998-12-23	2004-04-13	Esparma Gmbh	Hyaluronate lyase used for promoting penetration in topical agents
WO2006128618A1 (fr) *	2005-06-01	2006-12-07	Fidia Advanced Biopolymers S.R.L.	Formules d'acide lipoique et d'acide hyaluronique et/ou derives desdits acides pour la pharmacie et la cosmetique
WO2010130466A1 (fr) *	2009-05-14	2010-11-18	Fidia Farmaceutici S.P.A.	Acides hyaluroniques sulfatés comme agents de régulation de l'activité cytokinique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4303676A (en) *	1980-03-21	1981-12-01	Balazs Endre A	Hyaluronate based compositions and cosmetic formulations containing same
US5639738A (en) *	1992-02-20	1997-06-17	Hyal Pharmaceutical Corporation	Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
WO1996024362A1 (fr)	1995-02-07	1996-08-15	Shiseido Company, Ltd.	Agents anti-inflammatoires
JPH10195107A (ja) *	1997-01-10	1998-07-28	Shiseido Co Ltd	オリゴ硫酸化ヒアルロン酸
JPH11279042A (ja) *	1998-03-30	1999-10-12	Shiseido Co Ltd	皮膚外用剤
CN1116044C (zh) *	1998-06-24	2003-07-30	凌沛学	含有透明质酸钠的防粘连颗粒剂和粉雾剂及其制作方法
JP2000178196A (ja) *	1998-12-11	2000-06-27	Seikagaku Kogyo Co Ltd	新規ヒアルロニダーゼ阻害剤及び外用剤
WO2000069917A1 (fr) *	1999-05-18	2000-11-23	Maruho Kabushikikaisha	Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2?
AU2001242315A1 (en) *	2000-03-21	2001-10-15	Astion Development Aps	Chemical complex comprising a substituted pyridine carboxy derivative and a glucosaminoglycan
IL137559A (en) *	2000-07-27	2006-12-31	Amnon Sintov	A system for administering drugs through the skin
DE10053053A1 (de)	2000-10-19	2002-05-16	Knoell Hans Forschung Ev	Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
US20030162732A1 (en) *	2001-07-05	2003-08-28	Astion Development A/S	Combination of aminosugars and cysteine or cysteine derivatives
ITMI20020756A1 (it) *	2002-04-09	2003-10-09	Sinclair Pharma S R L	Composizioni farmaceutiche topiche per il trattamento delle dermatiti
BRPI0312331A2 (pt) *	2002-07-03	2016-06-28	Pericor Science Inc	composições de ácido hialurônico e métodos de emprego.
RU2329037C2 (ru) *	2003-02-14	2008-07-20	Комбинаторкс, Инкорпорейтед	Комбинированная терапия для лечения иммуновоспалительных заболеваний
DE102004002001A1 (de) *	2004-01-14	2005-08-11	Reinmüller, Johannes, Dr.med.	Mittel zur Behandlung von entzündlichen Erkrankungen
GB0411165D0 (en) *	2004-05-19	2004-06-23	Bionovate Ltd	Hyaluronic acid containing pharmaceutical or veterinary compounds
RU2302231C1 (ru) *	2006-02-08	2007-07-10	Александр Егорович Петренко	Глазные капли для лечения синдрома сухого глаза
ITPD20060219A1 (it) *	2006-05-31	2007-12-01	Fidia Farmaceutici	Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
ITMI20071724A1 (it) *	2007-09-05	2009-03-06	Fidia Farmaceutici	Formulazioni topiche antivirali in forma di gel bioadesivo

2009
- 2009-05-14 IT ITPD2009A000134A patent/IT1397246B1/it active
2010
- 2010-05-14 RU RU2011145992/15A patent/RU2543354C2/ru active
- 2010-05-14 ES ES10721126.0T patent/ES2601681T3/es active Active
- 2010-05-14 CN CN201080020708.3A patent/CN102427808B/zh active Active
- 2010-05-14 PT PT107211260T patent/PT2429515T/pt unknown
- 2010-05-14 SM SM20200522T patent/SMT202000522T1/it unknown
- 2010-05-14 SI SI201031318A patent/SI2429515T1/sl unknown
- 2010-05-14 SM SM20190015T patent/SMT201900015T1/it unknown
- 2010-05-14 EP EP10721126.0A patent/EP2429515B1/fr active Active
- 2010-05-14 ES ES18185228T patent/ES2808575T3/es active Active
- 2010-05-14 EP EP18185228.6A patent/EP3417855B1/fr active Active
- 2010-05-14 HR HRP20161574TT patent/HRP20161574T1/hr unknown
- 2010-05-14 WO PCT/EP2010/003050 patent/WO2010130468A1/fr not_active Ceased
- 2010-05-14 LT LTEP10721126.0T patent/LT2429515T/lt unknown
- 2010-05-14 CA CA2995610A patent/CA2995610C/fr active Active
- 2010-05-14 EP EP16178620.7A patent/EP3103449B1/fr active Active
- 2010-05-14 ES ES16178620T patent/ES2704921T3/es active Active
- 2010-05-14 CA CA2761628A patent/CA2761628C/fr active Active
- 2010-05-14 PL PL10721126T patent/PL2429515T3/pl unknown
- 2010-05-14 HU HUE10721126A patent/HUE030673T2/hu unknown
- 2010-05-14 US US13/320,000 patent/US9504708B2/en active Active
- 2010-05-14 US US13/320,000 patent/US20120121572A1/en active Granted
2014
- 2014-11-21 RU RU2014146977A patent/RU2673661C2/ru active
- 2014-11-21 RU RU2014146985A patent/RU2673066C2/ru active
2016
- 2016-10-27 US US15/336,498 patent/US10435483B2/en active Active
- 2016-12-14 SM SM201600455T patent/SMT201600455B/it unknown
2019
- 2019-08-26 US US16/550,810 patent/US11198741B2/en active Active

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995025751A1 (fr) *	1994-03-23	1995-09-28	Fidia Advanced Biopolymers Srl	Nouveaux polysaccharides sulfates du type heparine
GB2317182A (en) *	1996-09-11	1998-03-18	Johnson & Johnson Medical	Sulphated polysaccharides and uses thereof in medical treatment
WO1998045335A1 (fr) *	1997-04-04	1998-10-15	Fidia Advanced Biopolymers, S.R.L.	Composes d'acide hyaluronique n-sulfates, leurs derives et leur procede de preparation
DE19813234A1 (de) *	1998-03-26	1999-09-30	Knoell Hans Forschung Ev	Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
US6719986B1 (en) *	1998-12-23	2004-04-13	Esparma Gmbh	Hyaluronate lyase used for promoting penetration in topical agents
JP2001163789A (ja) *	1999-12-13	2001-06-19	Maruho Co Ltd	マトリックスメタロプロテアーゼ阻害用医薬組成物
WO2006128618A1 (fr) *	2005-06-01	2006-12-07	Fidia Advanced Biopolymers S.R.L.	Formules d'acide lipoique et d'acide hyaluronique et/ou derives desdits acides pour la pharmacie et la cosmetique
WO2010130466A1 (fr) *	2009-05-14	2010-11-18	Fidia Farmaceutici S.P.A.	Acides hyaluroniques sulfatés comme agents de régulation de l'activité cytokinique

Also Published As

Publication number	Publication date
US9504708B2 (en)	2016-11-29
US10435483B2 (en)	2019-10-08
SI2429515T1 (sl)	2016-12-30
CA2995610C (fr)	2020-04-28
RU2014146977A3 (fr)	2018-06-05
CA2761628A1 (fr)	2010-11-18
EP3417855B1 (fr)	2020-07-01
SMT202000522T1 (it)	2020-11-10
WO2010130468A1 (fr)	2010-11-18
RU2014146977A (ru)	2016-06-10
CN102427808A (zh)	2012-04-25
EP2429515A1 (fr)	2012-03-21
RU2543354C2 (ru)	2015-02-27
US11198741B2 (en)	2021-12-14
RU2673066C2 (ru)	2018-11-22
RU2011145992A (ru)	2013-06-20
ES2704921T3 (es)	2019-03-20
RU2014146985A (ru)	2016-06-10
HRP20161574T1 (hr)	2016-12-30
EP3103449B1 (fr)	2018-10-17
SMT201900015T1 (it)	2019-02-28
US20170107303A1 (en)	2017-04-20
CA2761628C (fr)	2018-04-10
US20200010573A1 (en)	2020-01-09
PT2429515T (pt)	2016-11-10
US20120121572A1 (en)	2012-05-17
RU2673661C2 (ru)	2018-11-29
RU2014146985A3 (fr)	2018-06-05
ES2601681T3 (es)	2017-02-15
LT2429515T (lt)	2016-12-12
IT1397246B1 (it)	2013-01-04
EP2429515B1 (fr)	2016-09-07
ITPD20090134A1 (it)	2010-11-15
CA2995610A1 (fr)	2010-11-18
ES2808575T3 (es)	2021-03-01
EP3417855A1 (fr)	2018-12-26
HUE030673T2 (hu)	2017-05-29
CN102427808B (zh)	2020-05-19
PL2429515T3 (pl)	2017-02-28
SMT201600455B (it)	2017-01-10
EP3103449A2 (fr)	2016-12-14

Publication	Publication Date	Title
EP3103449A3 (fr)	2017-02-15	Médicaments pour usage topique à base d'acide hyaluronique sulfaté comme agent d'activation ou d'inhibition de l'activité cytokinique
NZ627827A (en)	2016-02-26	Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
WO2010084115A3 (fr)	2013-04-25	Agents antiviraux
WO2004018419A3 (fr)	2004-06-03	Quinolinones de benzimidazole et leurs utilisations
WO2008084449A3 (fr)	2008-09-04	Articles absorbants jetables à porter, à côtés extensibles
WO2006122819A8 (fr)	2007-03-08	Utilisation d'inhibiteurs de ras
WO2005007078A3 (fr)	2009-04-09	Methodes d'inhibition du metapneumovirus humain et du coronavirus humain dans la prevention et le traitement du sras
WO2011109570A3 (fr)	2012-01-05	Dispositifs, système et procédés d'administration d'agent thérapeutique
MY144773A (en)	2011-10-31	6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor
WO2008149802A1 (fr)	2008-12-11	Agent anti-fatigue et composition orale comprenant chacun de l'andrographolide en tant que principe actif
WO2011076367A3 (fr)	2011-09-01	Composition antivirale synergique et utilisation associée
ATE554770T1 (de)	2012-05-15	Therapeutisches mittel gegen entzündliche darmerkrankungen
TW200505408A (en)	2005-02-16	Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2006053161A8 (fr)	2006-09-14	Utilisation de ranolazine en combinaison avec au moins un agent de remodelage pour inverser un remodelage du ventricule gauche dans le traitement de l'insuffisance cardiaque
EP4566667A3 (fr)	2025-09-03	Traitement d'une maladie cardiométabolique
EP2481429A3 (fr)	2013-07-03	Agents Perturbateures Du Systeme Vasculaire Actives Par MMP
WO2007080401A8 (fr)	2008-07-24	Dérivés de triazoloanilinopyrimidine pouvant être employés en tant qu'agents antiviraux
EP2392336A3 (fr)	2011-12-28	Utilisation de 24-norUDCA
MXPA02012320A (es)	2004-12-13	Uso de un agente para suprimir la infeccion y proliferacion del virus del sindrome de inmunodeficiencia humana.
MY151083A (en)	2014-04-04	Antiviral composition against flavivirus
PL1763363T3 (pl)	2009-12-31	Kompozycje farmaceutyczne zawierające diaminooksydazę
WO2006089664A3 (fr)	2006-11-02	Imidazoles substitues par heterocyclylamide
HK1203377A1 (en)	2015-10-30	Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
DK1534296T3 (da)	2011-08-15	Anvendelse af cilobradin eller de farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt
WO2011015881A3 (fr)	2011-08-18	Composition biocide

Legal Events

Date	Code	Title	Description
2016-11-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-11-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2016-12-14	AC	Divisional application: reference to earlier application	Ref document number: 2429515 Country of ref document: EP Kind code of ref document: P
2016-12-14	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2016-12-14	AX	Request for extension of the european patent	Extension state: BA ME RS
2017-01-13	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2017-02-15	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2017-02-15	AX	Request for extension of the european patent	Extension state: BA ME RS
2017-02-15	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 17/00 20060101ALI20170110BHEP Ipc: A61P 17/06 20060101ALI20170110BHEP Ipc: A61P 31/22 20060101ALI20170110BHEP Ipc: A61P 31/00 20060101ALI20170110BHEP Ipc: A61K 31/737 20060101ALI20170110BHEP Ipc: A61K 31/136 20060101AFI20170110BHEP Ipc: A61P 17/02 20060101ALI20170110BHEP Ipc: A61K 45/06 20060101ALI20170110BHEP Ipc: A61P 11/06 20060101ALI20170110BHEP
2017-07-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-08-23	17P	Request for examination filed	Effective date: 20170714
2017-08-23	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2017-12-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-01-24	17Q	First examination report despatched	Effective date: 20171222
2018-04-30	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-04-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-05-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 31/00 20060101ALI20180406BHEP Ipc: A61K 38/47 20060101ALI20180406BHEP Ipc: A61K 45/06 20060101ALI20180406BHEP Ipc: A61K 31/737 20060101ALI20180406BHEP Ipc: A61K 31/136 20060101AFI20180406BHEP Ipc: A61P 11/06 20060101ALI20180406BHEP Ipc: A61P 17/06 20060101ALI20180406BHEP Ipc: A61P 17/02 20060101ALI20180406BHEP Ipc: A61P 17/00 20060101ALI20180406BHEP Ipc: A61P 31/22 20060101ALI20180406BHEP
2018-05-23	INTG	Intention to grant announced	Effective date: 20180430
2018-08-31	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-09-14	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-09-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2018-10-17	AC	Divisional application: reference to earlier application	Ref document number: 2429515 Country of ref document: EP Kind code of ref document: P
2018-10-17	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2018-10-17	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2018-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2018-11-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-11-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602010054516 Country of ref document: DE Ref country code: AT Ref legal event code: REF Ref document number: 1053162 Country of ref document: AT Kind code of ref document: T Effective date: 20181115
2019-01-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH
2019-02-20	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20181017
2019-03-12	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1053162 Country of ref document: AT Kind code of ref document: T Effective date: 20181017
2019-03-20	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2704921 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190320
2019-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190117 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190117 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190217 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2019-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190118 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190217
2019-07-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602010054516 Country of ref document: DE
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2019-08-23	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-08-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2019-09-25	26N	No opposition filed	Effective date: 20190718
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2020-02-05	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20190531
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190514
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2020-05-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190514
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20100514
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181017
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230418
2025-07-03	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SM Payment date: 20250424 Year of fee payment: 16
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250529 Year of fee payment: 16
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250602 Year of fee payment: 16 Ref country code: GB Payment date: 20250527 Year of fee payment: 16
2025-07-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20250521 Year of fee payment: 16
2025-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250526 Year of fee payment: 16
2025-07-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20250601 Year of fee payment: 16
2025-07-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SK Payment date: 20250422 Year of fee payment: 16
2025-07-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CZ Payment date: 20250425 Year of fee payment: 16